Effects of glucocorticoids on oxidative stress-induced hippocampal cell death: Implications for the pathogenesis of Alzheimer's disease

Experimental Gerontology

Volumn 33, Issue 7-8, 1998, Pages 689-696

  Behl, Christian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Alzheimer's disease; Cell death; Free radicals; Glucocorticoids; NF B; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; FREE RADICAL; GLUCOCORTICOID; GLUTAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR;

ALZHEIMER DISEASE; BRAIN FUNCTION; CELL DEATH; CELL SURVIVAL; CONFERENCE PAPER; DRUG EFFECT; HIPPOCAMPUS; HUMAN; HUMAN CELL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR GENE;

ALZHEIMER DISEASE; ANIMALS; CELL DEATH; GLUCOCORTICOIDS; HIPPOCAMPUS; HUMANS; NEURONS; OXIDATIVE STRESS;

EID: 0032418502     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0531-5565(98)00019-9     Document Type: Conference Paper

References (60)

1. Ames B.N., Shigenaga M.K., Hagen T.M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc. Natl. Acad. Sci. USA. 90:1993;7915-7922.
2. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgem. Zeitschrift Psychiatr. Psychisch-Gerichtlichen Med. 64:1907;146-148.
3. Auphan N., Didonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids Inhibition of NF-κB activity through induction of IκB synthesis . Science. 270:1995;286-290.
4. Baeuerle P.A., Henkel T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 12:1994;141-179.
5. Baldwin A.S. The NF-kappa B and IkappaB proteins New discoveries and insights . Annu. Rev. of Immunol. 14:1996;649-683.
6. Ball M.J. Neuronal loss, neurofibrillary tangles, and granulovacuolar degeneration in the hippocampus with aging and dementia. Acta Neuropathol. 37:1977;111-118.
7. Ball M.J. Topographic distribution of neurofibrillary tangles and granulovacuolar degeneration in hippocampal cortex of aging and demented patients. A quantitative study. Acta Neuropathol. 42:1978;73-80.
8. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
9. Behl C., Davis J., Cole G.M., Schubert D. Vitamin E protects nerve cells from amyloid β protein toxicity. Biochem. Biophys. Res. Commun. 186:1992;944-952.
10. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell. 77:1994;817-822.
11. Behl C. Amyloid β-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res. 290:1997;471-480.
12. Behl, C., LEZOUALC'H, F., Trapp, T., Widmann, M., Skutella, T., and Holsboer, F., Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology 138, 101-106, 1997.
13. Braak H., Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1:1991;213-216.
14. Choi D.W. Excitotoxic cell death. J. Neurobiol. 23:1992;1261-1276.
15. Coleman P.D., Flood D.G. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol. Aging. 8:1987;521-545.
16. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
17. Davis J.B., Maher P. Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell line. Brain Res. 652:1994;169-173.
18. Ebadi M., Srinivasan S.K., Baxi M.D. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog. Neurobiol. 48:1996;1-19.
19. Evans R.M., Arriza J.L. A molecular framework for the action of glucocorticoid hormones in the nervous system. Neuron. 2:1989;1105-1112.
20. Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J., Hebert L.E., Hennekens C.H., Taylor J.O. Prevalence of Alzheimer's disease in a community population of older persons. JAMA. 262:1989;2551-2556.
21. Glenner G.G. Alzheimer's disease its proteins and genes . Cell. 52:1988;307-308.
22. Halliwell, B. and Gutteridge, J.M.C., Free Radicals in Biology and Medicine. 2nd ed., Oxford University Press, Oxford, 1989.
23. Halliwell B., Gutteridge J.M.C., Cross C.E. Free radicals, antioxidants, and human disease Where are we now? J. Lab. Clin. Med. 119:1992;598-620.
24. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell goth/cell killing. J. Immunol. Methods. 119:1989;203-210.
25. Harman D., Eddy D.E., Noffsinger J. Free radical theory of aging inhibition of amyloidosis in mice by antioxidants; Possible mechanism . J. Am. Geriatr. Soc. 24:1976;203-210.
26. Harris M.E., Hensley K., Butterfield A., Leedle R.A., Carney J.M. Direct evidence of oxidative injury produced by the Alzheimer's β-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 131:1995;193-202.
27. Hatzinger M., Z'brun A., Hemmeter U., Seifritz E., Baumann F., Holsboer-Trachsler E., Heuser I.J. Hypothalamic-pituitary-adrenal system function in patients with Alzheimer's disease. Neurobiol. Aging. 16:1995;205-209.
28. Heuser I.J., Gotthardt U., Schweiger U., Schmider J., Lammers C.H., Dettling M., Holsboer F. Age-associated changes of pituitary-adrenocortical hormone regulation in humans importance of gender . Neurobiol. Aging. 15:1994;227-231.
29. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr. Rev. 17:1996;187-205.
30. Hoyer S. Age as a risk factor for sporadic dementia of the Alzheimer type? Ann. NY Acad. Sci. 719:1994;248-256.
31. Johnson M., Stone D., Bush L., Hanson G., Gibb J. Glucocorticoids and 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity. J. Pharmacol. 161:1989;181-187.
32. Kaltschmidt B., BÄUERLE P.A., Kaltschmidt C. Potential involvement of the transcription factor NF-κB in neurological disorders. Mol. Aspects Med. 14:1993;171-190.
33. Koh J., Yang L.L., Cotman C.W. β Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 533:1990;315-320.
34. Koide T., Wieloch T.W., Siesjo B.K. Chronic dexamethasone pretreatment aggravates ischemic neuronal necrosis. J. Cereb. Blood. Flow Metab. 6:1990;395-404.
35. Landfield P.W. The role of glucocorticoids in brain aging and Alzheimer's disease An integrative physiological hypothesis . Exp. Gerontol. 29:1994;3-11.
36. Lezoualc'h F., Behl C. Transcription factor NF-κB Friend or foe of neurons? Mol. Psychiatry. 3:1998;15-20.
37. Lezoualc'h F., Sagara Y., Holsboer F., Behl C. High constitutive NF-κB activity mediates resistance to oxidative stress in neuronal cells. J. Neurosci. 18:1998;3224-3232.
38. Lipton S.A. Janus faces of NF-kappa B Neurodestruction versus neuroprotection . Nat. Med. 3:1997;20-22.
39. Markesbery W.R. Oxidative stress in Alzheimer's disease. Free Radic. Biol. Med. 23:1997;134-147.
40. Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg I., Rydel R. β-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12:1992;376-389.
41. McGeer E.G., McGeer P.L. The role of the immune system in neurodegenerative disorders. Move. Disord. 12:1996;855-858.
42. McIntosh, L.J., Hong, K.E., and Sapolsky, R.M., High glucocorticoid levels decrease some antioxidant enzyme activities in the adult rat brain. Soc. Neurosci. Abstr.21, 2129, 1995.
43. Melhorn R.J., Cole G. The free radical theory of aging A critical review . Adv. Free Radic. Biol. Med. 1:1985;165-223.
44. Morimoto B.H., Koshland D.E. Induction and expression of long-term and short-term neurosecretory potentiation in a neural cell line. Neuron. 5:1990;875-880.
45. Murphy T.H., Miyamoto M., Sastre A., Schnaar R.L., Coyle J.T. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron. 2:1989;1547-1558.
46. Olanow C.W. A radical hypothesis for neurodegeneration. Trends Neurosci. 16:1993;439-444.
47. Reul J.M.H.M., Dekloet E.R. Two receptor systems for corticosterone in rat brain. Endocrinology. 117:1985;2505-2511.
48. Sagara Y., Dargusch R., Klier F.G., Schubert D., Behl C. Increased antioxidant enzyme activity in amyloid β protein resistant cells. J. Neurosci. 16:1996;497-505.
49. Sapolsky R.M. Glucocorticoids, hippocampal damage and the glutamatergic synapse. Prog. Brain Res. 86:1990;13-23.
50. Sapolsky R.M., Packan D.R., Vale W.W. Glucocorticoid toxicity in the hippocampus In vitro demonstration . Brain Res. 453:1988;369-371.
51. Sapolsky R.M., Plotsky P.M. Hypercortisolism and its possible neural bases. Biol. Psychiatry. 27:1990;937-952.
52. Sapolsky R.M., Pulsinelli W.A. Glucocorticoids potentiate ischemic injury to neurons Therapeutic implications . Science. 229:1985;1397-1400.
53. Scheinman R.I., Cogswell P.C., Lofquist A.K., Baldwin A.A. Jr. Role of transcriptional activation of IκB in mediation of immunosuppression by glucocorticoids. Science. 270:1995;283-286.
54. Seckl J.R., Olsson T. Glucocorticoid hypersecretion and the age-impaired hippocampus Cause or effect? J. Endocrinol. 145:1995;201-211.
55. Sies H. Strategies of antioxidant defense. Eur. J. Biochem. 215:1993;213-219.
56. Terry R.D. Alzheimer's disease. Davis R.L., Robertson D.M. Textbook of Neuropathology. 1985;824-841 Williams & Wilkins, Baltimore.
57. Unlap M.T., Jope R.S. Dexamethasone attenuates NF-kappaB DNA binding activity without inducing IkappaB levels in rat brain in vivo. Mol. Brain Res. 45:1997;83-89.
58. van der Burg B., Liden J., Okret S., Delaunay F., Wissink S., van der Saag J.-A. Nuclear factor-κB repression in antiinflammatory and immunosuppression by glucocorticoids. Trends Endocrinol. Metab. 8:1997;152-157.
59. Yankner B.A., Duffy L., Kirschner D. Neurotrophic and neurotoxic effects of amyloid β protein Reversal by tachykinin neuropeptides . Science. 250:1990;279-282.
60. Yankner B.A. Mechanism of neuronal degeneration in Alzheimer's disease. Neuron. 16:1996;921-932.